Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 7 de 7
1.
Gastroenterology ; 144(1): 112-121.e2, 2013 Jan.
Article En | MEDLINE | ID: mdl-23041322

BACKGROUND & AIMS: Autosomal recessive polycystic kidney disease (ARPKD), the most common ciliopathy of childhood, is characterized by congenital hepatic fibrosis and progressive cystic degeneration of kidneys. We aimed to describe congenital hepatic fibrosis in patients with ARPKD, confirmed by detection of mutations in PKHD1. METHODS: Patients with ARPKD and congenital hepatic fibrosis were evaluated at the National Institutes of Health from 2003 to 2009. We analyzed clinical, molecular, and imaging data from 73 patients (age, 1-56 years; average, 12.7 ± 13.1 years) with kidney and liver involvement (based on clinical, imaging, or biopsy analyses) and mutations in PKHD1. RESULTS: Initial symptoms were liver related in 26% of patients, and others presented with kidney disease. One patient underwent liver and kidney transplantation, and 10 others received kidney transplants. Four presented with cholangitis and one with variceal bleeding. Sixty-nine percent of patients had enlarged left lobes on magnetic resonance imaging, 92% had increased liver echogenicity on ultrasonography, and 65% had splenomegaly. Splenomegaly started early in life; 60% of children younger than 5 years had enlarged spleens. Spleen volume had an inverse correlation with platelet count and prothrombin time but not with serum albumin level. Platelet count was the best predictor of spleen volume (area under the curve of 0.88905), and spleen length corrected for patient's height correlated inversely with platelet count (R(2) = 0.42, P < .0001). Spleen volume did not correlate with renal function or type of PKHD1 mutation. Twenty-two of 31 patients who underwent endoscopy were found to have varices. Five had variceal bleeding, and 2 had portosystemic shunts. Forty-percent had Caroli syndrome, and 30% had an isolated dilated common bile duct. CONCLUSIONS: Platelet count is the best predictor of the severity of portal hypertension, which has early onset but is underdiagnosed in patients with ARPKD. Seventy percent of patients with ARPKD have biliary abnormalities. Kidney and liver disease are independent, and variability in severity is not explainable by type of PKHD1 mutation; ClinicalTrials.gov number, NCT00068224.


Hypertension, Portal/physiopathology , Liver Cirrhosis/congenital , Liver Cirrhosis/pathology , Polycystic Kidney, Autosomal Recessive/genetics , Receptors, Cell Surface/genetics , Adolescent , Adult , Alkaline Phosphatase/blood , Child , Child, Preschool , Cholangiopancreatography, Magnetic Resonance , Endoscopy, Gastrointestinal , Esophageal and Gastric Varices/etiology , Female , Humans , Hypertension, Portal/blood , Hypertension, Portal/complications , Infant , Kidney Transplantation , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/genetics , Liver Transplantation , Male , Middle Aged , Mutation , Organ Size , Platelet Count , Polycystic Kidney, Autosomal Recessive/complications , Portal Pressure , Prothrombin Time , Serum Albumin , Severity of Illness Index , Splenomegaly/diagnostic imaging , Ultrasonography, Doppler, Color , Young Adult , gamma-Glutamyltransferase/blood
2.
Clin Nutr ; 31(3): 359-63, 2012 Jun.
Article En | MEDLINE | ID: mdl-22154461

BACKGROUND & AIMS: Children with Cushing syndrome present with growth delay and excess adiposity that tends to be generalized rather than centripetal. There are no prospective studies of this phenotype as it evolves before and after treatment in children. The aims of this study were to evaluate children prior to and one-year after surgical cure compared to controls and to determine fasting insulin levels and their possible association with waist circumference and waist-height ratio, pre- and post-cure of Cushing syndrome. METHODS: 30 children with Cushing syndrome were evaluated prior to and one-year post-treatment and compared to 14 age and body mass index-matched controls. RESULTS: Only triceps skin fold z- score showed a significant difference between patients with active Cushing syndrome and controls. A positive correlation between fasting insulin levels and waist circumference z- score was found for children with Cushing syndrome; this association persisted one-year following cure. CONCLUSIONS: Unlike adults affected with Cushing syndrome, upper arm muscle area of children with Cushing syndrome did not differ from obese children without Cushing syndrome. The persistence of a positive correlation between waist circumference and fasting insulin despite remission of Cushing syndrome suggests that children with a history of Cushing syndrome may have an increased risk for adverse long-term effects of increased abdominal fat mass.


Cushing Syndrome/blood , Cushing Syndrome/surgery , Insulin/blood , Obesity, Abdominal/etiology , Abdominal Fat , Adiposity , Adolescent , Adrenal Gland Neoplasms/physiopathology , Adrenal Gland Neoplasms/surgery , Adrenalectomy , Body Mass Index , Child , Cohort Studies , Cushing Syndrome/etiology , Cushing Syndrome/physiopathology , Female , Follow-Up Studies , Humans , Hypophysectomy , Male , Pituitary Neoplasms/physiopathology , Pituitary Neoplasms/surgery , Remission Induction , Skinfold Thickness , Waist Circumference
3.
Am J Clin Nutr ; 93(1): 47-56, 2011 Jan.
Article En | MEDLINE | ID: mdl-21048060

BACKGROUND: Isolated methylmalonic acidemia (MMA) is managed by dietary protein restriction and medical food supplementation. Resting energy expenditure (REE) can be depressed in affected individuals for undefined reasons. OBJECTIVE: The objective was to document the spectrum of nutritional approaches used to treat patients with MMA, measure REE, and analyze the dependence of REE on body composition, biochemical, and nutritional variables. DESIGN: Twenty-nine patients with isolated MMA (22 mut, 5 cblA, 2 cblB; 15 males, 14 females; age range: 2-35 y) underwent evaluation. REE was measured with open-circuit calorimetry and compared with predicted values by using age-appropriate equations. RESULTS: Nutritional regimens were as follows: protein restriction with medical food (n = 17 of 29), protein restriction with medical food and supplemental isoleucine or valine (n = 5 of 29), or the use of natural protein alone for dietary needs (n = 7 of 29). Most mut patients had short stature and higher percentage fat mass compared with reference controls. Measured REE decreased to 74 ± 13.6% of predicted (P < 0.001) in the ≤ 18-y group (n = 22) and to 83 ± 11.1% (P = 0.004) in patients aged >18 y (n = 7). Linear regression modeling suggested that age (P = 0.001), creatinine clearance (P = 0.01), and height z score (P = 0.04) accounted for part of the variance of measured REE per kilogram of fat-free mass (model R² = 0.66, P < 0.0001). CONCLUSIONS: There is wide variation in the dietary treatment of MMA. Standard predictive equations overestimate REE in this population primarily due to their altered body composition and decreased renal function. Defining actual energy needs will help optimize nutrition and protect individuals from overfeeding. This trial is registered at clinicaltrials.gov as NCT00078078.


Amino Acid Metabolism, Inborn Errors , Energy Metabolism , Adolescent , Adult , Amino Acid Metabolism, Inborn Errors/diet therapy , Amino Acid Metabolism, Inborn Errors/metabolism , Body Composition , Body Mass Index , Child , Child, Preschool , Dietary Proteins/administration & dosage , Female , Humans , Linear Models , Male
4.
Clin J Am Soc Nephrol ; 5(6): 972-84, 2010 Jun.
Article En | MEDLINE | ID: mdl-20413436

BACKGROUND AND OBJECTIVES: Renal function and imaging findings have not been comprehensively and prospectively characterized in a broad age range of patients with molecularly confirmed autosomal recessive polycystic kidney disease (ARPKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Ninety potential ARPKD patients were examined at the National Institutes of Health Clinical Center. Seventy-three fulfilled clinical diagnostic criteria, had at least one PKHD1 mutation, and were prospectively evaluated using magnetic resonance imaging (MRI), high-resolution ultrasonography (HR-USG), and measures of glomerular and tubular function. RESULTS: Among 31 perinatally symptomatic patients, 25% required renal replacement therapy by age 11 years; among 42 patients who became symptomatic beyond 1 month (nonperinatal), 25% required kidney transplantation by age 32 years. Creatinine clearance (CrCl) for nonperinatal patients (103 +/- 54 ml/min/1.73 m(2)) was greater than for perinatal patients (62 +/- 33) (P = 0.002). Corticomedullary involvement on HR-USG was associated with a significantly worse mean CrCl (61 +/- 32) in comparison with medullary involvement only (131 +/- 46) (P < 0.0001). Among children with enlarged kidneys, volume correlated inversely with function, although with wide variability. Severity of PKHD1 mutations did not determine kidney size or function. In 35% of patients with medullary-only abnormalities, standard ultrasound was normal and the pathology was detectable with HR-USG. CONCLUSIONS: In ARPKD, perinatal presentation and corticomedullary involvement are associated with faster progression of kidney disease. Mild ARPKD is best detected by HR-USG. Considerable variability occurs that is not explained by the type of PKHD1 mutation.


Genes, Recessive , Kidney/pathology , Kidney/physiopathology , Polycystic Kidney Diseases/genetics , Receptors, Cell Surface/genetics , Adolescent , Adult , Biomarkers/blood , Biomarkers/urine , Child , Child, Preschool , Creatinine/urine , Cystatin C/blood , DNA Mutational Analysis , Disease Progression , Female , Genetic Predisposition to Disease , Glomerular Filtration Rate , Humans , Infant , Kaplan-Meier Estimate , Kidney/diagnostic imaging , Kidney Tubules/pathology , Kidney Tubules/physiopathology , Magnetic Resonance Imaging , Male , Middle Aged , National Institutes of Health (U.S.) , Organ Size , Pedigree , Phenotype , Polycystic Kidney Diseases/pathology , Polycystic Kidney Diseases/physiopathology , Polycystic Kidney Diseases/therapy , Prospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Time Factors , Ultrasonography , United States , Young Adult
5.
N Engl J Med ; 358(6): 592-604, 2008 Feb 07.
Article En | MEDLINE | ID: mdl-18256394

BACKGROUND: Hutchinson-Gilford progeria syndrome is a rare, sporadic, autosomal dominant syndrome that involves premature aging, generally leading to death at approximately 13 years of age due to myocardial infarction or stroke. The genetic basis of most cases of this syndrome is a change from glycine GGC to glycine GGT in codon 608 of the lamin A (LMNA) gene, which activates a cryptic splice donor site to produce abnormal lamin A; this disrupts the nuclear membrane and alters transcription. METHODS: We enrolled 15 children between 1 and 17 years of age, representing nearly half of the world's known patients with Hutchinson-Gilford progeria syndrome, in a comprehensive clinical protocol between February 2005 and May 2006. RESULTS: Clinical investigations confirmed sclerotic skin, joint contractures, bone abnormalities, alopecia, and growth impairment in all 15 patients; cardiovascular and central nervous system sequelae were also documented. Previously unrecognized findings included prolonged prothrombin times, elevated platelet counts and serum phosphorus levels, measured reductions in joint range of motion, low-frequency conductive hearing loss, and functional oral deficits. Growth impairment was not related to inadequate nutrition, insulin unresponsiveness, or growth hormone deficiency. Growth hormone treatment in a few patients increased height growth by 10% and weight growth by 50%. Cardiovascular studies revealed diminishing vascular function with age, including elevated blood pressure, reduced vascular compliance, decreased ankle-brachial indexes, and adventitial thickening. CONCLUSIONS: Establishing the detailed phenotype of Hutchinson-Gilford progeria syndrome is important because advances in understanding this syndrome may offer insight into normal aging. Abnormal lamin A (progerin) appears to accumulate with aging in normal cells. (ClinicalTrials.gov number, NCT00094393.)


Phenotype , Progeria/physiopathology , Adolescent , Blood Chemical Analysis , Child , Child, Preschool , Disease Progression , Female , Growth , Humans , Infant , Male , Progeria/blood , Progeria/pathology
6.
Ann Behav Med ; 33(2): 124-31, 2007 Apr.
Article En | MEDLINE | ID: mdl-17447864

BACKGROUND: Interactive video games are a popular alternative to physical activity in youth. One advancement in computer games are interactive games that use physical activity as a game playing controller, combining exercise and entertainment, or exertainment. PURPOSE: This study tested the reinforcing value and activity levels of interactive dance and bicycle race games in 18 overweight and 17 nonoverweight 8- to 12-year-old youth. METHODS: Reinforcing value was studied using a behavioral choice paradigm that provided children the opportunity to respond on progressive ratio schedules of reinforcement for a choice of either playing the video dance or bicycle game using a handheld video game controller or one of three options: dancing or bicycling alone, dancing or bicycling while watching a video, or playing the interactive dance or bicycle game. Reinforcing value was defined in relationship to the amount of responding children engaged in for either choice. RESULTS: Results showed the interactive dance game was more reinforcing than dancing alone or dancing while watching the video (p = .003), but there was no difference across bicycling conditions. Nonoverweight youth were more active when given the opportunity to play the interactive dance game than overweight children (p = .05). CONCLUSIONS: These results suggest that children may be motivated to be active when given the opportunity to play an interactive dance game.


Bicycling/psychology , Choice Behavior , Dancing/psychology , Overweight/psychology , Video Games , Body Mass Index , Child , Female , Humans , Male , Motivation , Motor Activity
7.
J Clin Pharmacol ; 43(4): 414-22, 2003 Apr.
Article En | MEDLINE | ID: mdl-12723462

Antiretroviral agents may participate in drug interactions that influence the efficacy and toxicity of other antiretrovirals, as well as pharmacologic treatments of coincident or complicating diseases. The viral protease inhibitor, ritonavir, may cause drug interactions by inhibiting the activity of cytochrome P450-3A (CYP3A) isoforms. In a single-dose, blinded, four-way crossover study, 10 healthy volunteer subjects received 50 mg of trazodone hydrochloride or matching placebo concurrent with low-dose ritonavir (four doses of 200 mg each) or with placebo. Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE). Coadministration of trazodone with ritonavir increased sedation, fatigue, and performance impairment compared to trazodone plus placebo; differences reached significance only for the digitsymbol substitution test. Three subjects experienced nausea, dizziness, or hypotension when trazodone was given with ritonavir; 1 of these subjects also experienced syncope. Thus short-term low-dose administration of ritonavir impairs oral clearance of trazodone and increases the occurrence of adverse reactions. The findings are consistent with impairment of CYP3A-mediated trazodone metabolism by ritonavir.


HIV Protease Inhibitors/administration & dosage , HIV Protease Inhibitors/pharmacology , Ritonavir/administration & dosage , Ritonavir/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacokinetics , Trazodone/pharmacokinetics , Administration, Oral , Adult , Area Under Curve , Chromatography, High Pressure Liquid , Cross-Over Studies , Drug Interactions , Drug Therapy, Combination , Female , Half-Life , Humans , Male , Middle Aged , Selective Serotonin Reuptake Inhibitors/adverse effects , Selective Serotonin Reuptake Inhibitors/blood , Time Factors , Trazodone/adverse effects , Trazodone/blood
...